LLY Lilly(Eli) & Co

$LLY has to bribe - not educate physicians to Rx orforglipron as a lousy med for obesity. It may have a usage in diabetes .. but a very poor obesity medicine .. if it can escape liver enzymes issue once thousands on top dose. $VKTX 2735 is a different animal and people who are willing to wait another year will gain a lot. Although I doubt VK will stay independent till then Don’t r / o Lilly looking into it

$LLY $VKTX People here who don’t understand how clinical trials done and get confused by blindness don’t appreciate how much info CEOs gather from ongoing trials , particularly when placebo is small portion or easy to isolate. $VKTX CEO hinted to vomit rate from maintenance 21 wk data as early as June at MS notes . See below. “While more aggressive titration schedule could result in less favorable tolerability, mgt. has indicated they would not expect a materially different tolerability profile relative to Phase 2 “ He repeatedly talked about wt loss maintenance and tolerability wks preceding data release Astute people pay attention

$LLY $VKTX $PFE is toasted. Bourla will not get > 2-5% of market and not Vk as some analysts predict. I can’t see but Lilly making the final move on VK within a year from now to save hundreds of billions in MC drop long term if vk2735 succeeds commercially . Which he highly likely. Vk could simply cut price by $50 And wreck havoc on Lilly. That witnessed what happened to $NVO and will not just watch.

$LLY $NVO $OZEM This article is complete bullshit. Wegovy pill was Much more effective thab Foundayo in trials. Foundayo also has a higher drop out rate.

Rotation into defensive sectors like healthcare this morning. Here's $LLY which continues to set up constructively.

$LLY $NVO $VKTX Foundayo is so shit. 11% weight loss as a standalone therapy and as maintenance it barely beats placebo with people gaining weight again. Wild how Lilly can take a weak drug and slap their name on it and do a billion in sales this year so far alone with it just having been approved and probably 3-5x more than that next year. Enjoy the next couple years because if Ricks doesn’t make a deal with viking they are losing the oral market and a chunk of the SC market. 1 trillion market cap - big tree fall hard.

$LLY Eli Lilly’s Foundayo: 64.2K → 57.9K weekly scripts (-9.8%), reportedly. Heavy marketing, discounts and free samples can drive trials. But are patients staying and refilling? That matters more than a launch spike. $NVO’s Wegovy pill still leads oral scripts. #Foundayo

what $lly is going to fast food and sugar lobby ai agents will do to consumer companies hiding behind bad service and bloated support cord cutting will accelerate the iphone generation got themselves their cancel weapon

LLY Vs NVO: Foundayo Beats Novo’s Oral Semaglutide On Weight Loss, Blood Sugar In New Finding $LLY $NVO $OZEM https://stocktwits.com/news/equity/markets/lly-vs-nvo-foundayo-oral-semaglutide-weight-loss-blood-sugar-new-finding/cZMmU5cRBgI

$LLY everyone should be taking Retatrutide to lose fat. Will be buying 1k shares after a stock split

$LLY No one will need to take on risk day trading ever, just put in LLY and enjoy the Ride!

$LLY | Eli Lilly Drug Combo Spurs Record Weight Loss In Diabetes Study - Participants Taking eloraTZP Lowered Their A1C By Up To Avg Of 2.9% Vs. 2.4% With Tirzepatide 15mg - At 48 Weeks, All Combinations Of eloraTZP Met Primary & Secondary Endpoints - Participants Taking eloraTZP Lost Up To Avg Of 54.1 Lbs (23.3%) Vs. 34.4lbs (14.8%) With Tirzepatide 15mg - Plans To Initiate Phase 3 Studies Of eloraTZP Co-Formulation Product By 2026 End Using Optimized Escalation Schedule

In the Phase 3 REIMAGINE 5 trial, adults w/ type 2 diabetes taking the 1 mg/ 1 mg dose of CagriSema lost an est’d 12.4% of their body weight after 60 weeks, compared w/ 9.1% for patients receiving 5 mg of tirzepatide, which is the active ingredient in $LLY Mounjaro & Zepbound. $NVO CariSema delivered non-inferior blood-sugar reduction For Novo investors, the timing holds significance since CagriSema is one of the company's most important next-gen obesity assets, & the FDA is expected to decide on its weight-mgmt application in 4Q25, w/ the company targeting a launch early next year In the separate Phase 3 REDEFINE 9 study, the same 1 mg/1 mg dose produced est’d weight loss of 21% after 68 weeks in adults w/ overweight or obesity, compared w/ 2.0% for placebo. The drug combines cagrilintide, a long-acting amylin receptor agonist, w/ semaglutide, the GLP-1 ingredient in Wegovy.

$LLY - (Bloomberg) - Investors should expect Eli Lilly & Co. to strike slightly larger deals, along the lines of its $7.8 billion acquisition of Centessa Pharmaceuticals Plc, as it casts a wide net for assets in the “white spaces” of science, Chief Executive Officer Dave Ricks said. https://www.bloomberg.com/news/articles/2026-09-28/lilly-ceo-eyes-bigger-deals-in-hunt-for-pharma-s-white-spaces?srnd=homepage-americas

Ohhh, okay; now nobody likes these. Drunk on AI again, all of a sudden! Hilarious. These are killers. Just wait. $LLY $TRMD $NAT $BWET

The rotation into defensive sectors like healthcare continues. Here's $LLY following through.

During times of market weakness, it's always good to pay attention to what names are still strong. Right now $LLY matches that description. Breaking out to the upside and looks like an easy drift up to highs.

$LLY yesterday played LLY calls. And she’s ripping overnight as nice little inverse market weakness trade See how PPI works out

$LLY - Great off set for $NVDA . When tech and the market sells off often times healthcare is green. Long both with highest % and conviction for growth

$LLY only into those with a shareholder-oriented ceo not $VKTX and its ATM milking-shareholders obsession. $SPY